NSEUpdates24 Jul 2026 · 24 Jul 2026, 08:55 pm
Updates
Piramal Pharma Limited · PPLPHARMA
✦ AI SummaryRegulatory
Piramal Pharma Limited has temporarily suspended operations at its manufacturing facilities in Ahmedabad, Gujarat, due to heavy rainfall and flooding. The company has initiated actions to assess the situation and resume operations safely. The affected facilities account for less than 3% of the company's consolidated revenues.
Analysis Scores
Earnings Impact2/10
Growth Catalyst1/10
Governance Concern1/10
Regulatory Risk2/10
Balance Sheet Risk1/10
Liquidity Impact8/10
Market Sentiment5/10
✦ Ask a Question
Ask anything about this announcement — AI will answer based on the filing content.
Full Announcement
Please refer attachment.
Attachments (1)
📄pdf
Download →
PIRAMALPHARMA_24072026205512_Reg30IntimationAhmedabadoperationalimpact.pdf
View document text
24 July, 2026
BSE Limited National Stock Exchange of India Limited
P.J. Towers, Dalal Street, Fort, Exchange Plaza, Bandra-Kurla Complex,
Mumbai- 400 001 Bandra (East), Mumbai – 400 051
BSE scrip code: 543635 NSE symbol: PPLPHARMA
Sub: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure
Requirements) Regulations, 2015 – Temporary suspension of operations at Company’s
facilities located at Ahmedabad, Gujarat
Dear Sir / Madam,
This is to inform that due to exceptionally heavy rainfall and flooding across parts of Gujarat
resulting in waterlogging, the operations at the Company's manufacturing facilities located at
Plot Nos. 18 and 19 – PHARMEZ - Pharmaceutical Special Economic Zone, Village Matoda,
Sarkhej Bawla, NH 8A, Taluka Sanand, Ahmedabad - 382 213, Gujarat, India, have been
temporarily suspended as a precautionary measure. All employees, including contract staff, at
the affected facilities are safe.
The Company has initiated necessary actions to assess the condition of the facilities and to
facilitate a safe and orderly resumption of operations at the earliest. The extent of the impact,
if any, on assets, operations is currently under evaluation. Subject to the improvement in the
weather conditions, the operations are expected to gradually normalize over the next few days.
The assets at the affected facilities are adequately covered under the Company's insurance
policies.
For context, the aforesaid facilities together account for less than 3% of the Company's
consolidated revenues.
The Company shall provide further updates, including any material developments or financial
implications, as appropriate.
This is for your information and records
Thanking you,
Yours truly,
For Piramal Pharma Limited
Maneesh Sharma
Company Secretary & Compliance Officer
Piramal Pharma Limited
CIN: L24297MH2020PLC338592
Registered Office: Ananta Building, Piramal Corporate Park, Opp. Fire Brigade, Kamani Junction, LBS Marg, Kurla (West), Mumbai - 400070,
Maharashtra, India
T +91 22 3802 3000 / 4000
Piramalpharma.com